New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2025, WHO updated recommendations on HIV clinical management: recommendations for a public health approach
View latest version (2025)Bibliographic Info
GuidelineUpdated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV
Year of Publication2018
Issuing InstitutionWHO
Recommendation
Status
Retired
Recommended in favor
Conditional
Certainty of evidence
Low
dolutegravir (DTG) in combination with an optimized nucleoside reverse-transcriptase inhibitor backbone is recommended as the preferred second-line regimen for children with approved DTG dosing for whom non-DTG-based regimens are failing
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach
Year2013
InstitutionWHO